Literature DB >> 28572255

Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Ann H Partridge1, Lisa A Carey2.   

Abstract

This CCR Focus highlights areas in breast cancer research with the greatest potential for clinical and therapeutic application. The articles in this CCR Focus address the state of the science in a broad range of areas with a focus on "hot" although sometimes controversial topics, unanswered questions, and unmet need. From mutational signatures, the cancer genomic revolution, and new inroads in immunotherapy for breast cancer to unique concerns of vulnerable populations as well as national and global health disparities, these works represent much of the promise of breast cancer research as well as the challenges in the coming years. Each review focuses not only on recent discoveries but also on putting the topic in context, including limitations to overcome. This overview is designed to further contextualize the highlighted issues within the broader research landscape. We also present new information from a poll of ALLIANCE for Clinical Trials in Oncology Breast Committee members regarding the most needed and viable potential future National Cancer Institute (NCI)-supported clinical trials in breast cancer. The great challenge is to translate the potential benefits of greater scientific knowledge reflected in this CCR Focus section into improvements in outcomes for individuals and populations with breast cancer. A unifying theme across the six articles contained in this CCR Focus is the increasingly recognized value and necessity of collaboration across disciplines from bench to bedside to populations. Only continued and iteratively amplified scientific, clinical, and governmental commitment to creating, testing, and implementing new knowledge will reduce the global morbidity and mortality of breast cancer. Clin Cancer Res; 23(11); 2611-6. ©2017 AACRSee all articles in this CCR Focus section, "Breast Cancer Research: From Base Pairs to Populations." ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 28572255      PMCID: PMC5512575          DOI: 10.1158/1078-0432.CCR-16-2633

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.

Authors:  Stephen J Luen; Peter Savas; Stephen B Fox; Roberto Salgado; Sherene Loi
Journal:  Pathology       Date:  2016-12-31       Impact factor: 5.306

2.  Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.

Authors:  Ivana Sestak; Jack Cuzick; Mitch Dowsett; Elena Lopez-Knowles; Martin Filipits; Peter Dubsky; John Wayne Cowens; Sean Ferree; Carl Schaper; Christian Fesl; Michael Gnant
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

3.  Atezolizumab Extends Survival for Breast Cancer.

Authors: 
Journal:  Cancer Discov       Date:  2017-04-04       Impact factor: 39.397

4.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Authors:  Ann H Partridge; Philip S Wang; Eric P Winer; Jerry Avorn
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

5.  Mutational Signatures in Breast Cancer: The Problem at the DNA Level.

Authors:  Serena Nik-Zainal; Sandro Morganella
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

6.  HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Authors:  Antonio Llombart-Cussac; Javier Cortés; Laia Paré; Patricia Galván; Begoña Bermejo; Noelia Martínez; Maria Vidal; Sònia Pernas; Rafael López; Montserrat Muñoz; Paolo Nuciforo; Serafín Morales; Mafalda Oliveira; Lorena de la Peña; Alexandra Peláez; Aleix Prat
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

7.  Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

Authors:  Lisa A Carey; Donald A Berry; Constance T Cirrincione; William T Barry; Brandelyn N Pitcher; Lyndsay N Harris; David W Ollila; Ian E Krop; Norah Lynn Henry; Douglas J Weckstein; Carey K Anders; Baljit Singh; Katherine A Hoadley; Michael Iglesia; Maggie Chon U Cheang; Charles M Perou; Eric P Winer; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

8.  Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.

Authors:  Tari A King; Jaclyn P Lyman; Mithat Gonen; Amy Voci; Marina De Brot; Camilla Boafo; Amy Pratt Sing; E Shelley Hwang; Michael D Alvarado; Minetta C Liu; Judy C Boughey; Kandace P McGuire; Catherine H Van Poznak; Lisa K Jacobs; Ingrid M Meszoely; Helen Krontiras; Gildy V Babiera; Larry Norton; Monica Morrow; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

9.  Clock-like mutational processes in human somatic cells.

Authors:  Ludmil B Alexandrov; Philip H Jones; David C Wedge; Julian E Sale; Peter J Campbell; Serena Nik-Zainal; Michael R Stratton
Journal:  Nat Genet       Date:  2015-11-09       Impact factor: 38.330

10.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

View more
  4 in total

1.  Identification of DHX36 as a tumour suppressor through modulating the activities of the stress-associated proteins and cyclin-dependent kinases in breast cancer.

Authors:  Yinduo Zeng; Tao Qin; Valentina Flamini; Cui Tan; Xinke Zhang; Yizi Cong; Emily Birkin; Wen G Jiang; Herui Yao; Yuxin Cui
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  A novel immune prognostic index for stratification of high-risk patients with early breast cancer.

Authors:  Hannah Lee; Mi Jeong Kwon; Beom-Mo Koo; Hee Geon Park; Jinil Han; Young Kee Shin
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

3.  Effectiveness of virtual reality-based interventions in rehabilitation management of breast cancer survivors: protocol of a systematic review and meta-analysis.

Authors:  Xiaofan Bu; Peter H F Ng; Qi Chen; Andy S K Cheng; Wenjing Xu; Ying Tong; Qingping Tang; Xiangyu Liu
Journal:  BMJ Open       Date:  2022-02-16       Impact factor: 2.692

4.  Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.

Authors:  Gagan Gupta; Caroline Dasom Lee; Mary L Guye; Robert E Van Sciver; Michael P Lee; Alex C Lafever; Anthony Pang; Angela M Tang-Tan; Janet S Winston; Billur Samli; Rick J Jansen; Richard A Hoefer; Amy H Tang
Journal:  Ann Breast Cancer Ther       Date:  2020-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.